. 2023 Sep 13;6(9):e2329583. doi: 10.1001/jamanetworkopen.2023.29583

Table 2. Results of Base Case Analysis.

Strategy	Annual fatal overdose rate per 1000 people^a	Remaining undiscounted LYs per person^b	Total discounted cost per person, $^b	Change in discounted cost per person, $^b	Remaining discounted QALYs per person^b	Change in remaining discounted QALYs per person^b	ICER ($/LY)^b	ICER ($/QALY)^b
No medication treatment strategy	7.77	20.54	241 070	NA	8.32	NA	NA	NA
Treatment with transmucosal buprenorphine strategy	6.27	27.44	304 700	63 630	11.55	3.22	18 380	19 740
Treatment with extended-release buprenorphine strategy	6.42	27.39	308 700	4000	11.52	−0.03	Dominated^c	Dominated^c

Abbreviations: ICER, incremental cost-effectiveness ratio; LY, life-years; NA, not applicable; QALY, quality-adjusted life-years.

^{^a}

Calculated over the first 10 years of the simulation.

^{^b}

Costs and ICERs were rounded to nearest $10 and QALYs and LYs to nearest 0.01.

^{^c}

A strategy was considered dominated when costing more and achieving a lower QALY than the next least expensive strategy.